CLINUVEL Kommuniqué VI
Der letzte Monat war eine tragische Lektion in Bezug auf die Herausforderungen...
Read More
Vitiligo Communiqué IV
CLINUVEL’s fourth Vitiligo Communiqué discusses the long-term consequences, both physical and psychological,...
Read More
CLINUVEL Kommuniqué V
CLINUVELs fünftes Nachrichtenkommuniqué für 2021. Bespricht EPP, klinisches Programm, IR-Update und mehr.
Read More
CLINUVEL Communiqué V
CLINUVEL’s fifth News Communiqué for 2021. Discusses EPP, clinical program, IR update...
Read More
CLINUVEL Kommuniqué IV
Sehr geehrte Aktionärinnen und Aktionäre, liebe Freunde, Einleitung Zufrieden blicken wir auf...
Read More
CLINUVEL Communiqué IV
Dear Shareholders, Friends Introduction With satisfaction, we look back at an eventful...
Read More
SCIENTIFIC COMMUNIQUÉ XI: Developing Novel Treatments for Arterial Ischaemic Stroke Patients
Abstract One in four people globally will suffer from a stroke in...
Read More
CLINUVEL Kommuniqué III
Sehr geehrte Aktionärinnen und Aktionäre, liebeFreunde, EINFÜHRUNG Während des Lockdown hatte unser...
Read More
CLINUVEL Communiqué III
Dear shareholders, friends, INTRODUCTION During the lockdowns our team has had plenty...
Read More
SCIENTIFIC COMMUNIQUÉ X: Photoprotection and the significance of Minimal Erythema Dose (MED) testing
May 2021 ABSTRACT The sun continuously emits radiant energy across the solar...
Read More
CLINUVEL Kommuniqué II
Liebe Aktionäre, Freunde Wir begrüßen viele neue Aktionäre, insbesondere die große Anzahl...
Read More
CLINUVEL Communiqué II
Dear shareholders, friends We welcome many new shareholders, especially the large number...
Read More
SCIENTIFIC COMMUNIQUÉ IX
Beyond Pigment, the Melanocortin 1 Receptor (MC1R) in DNA Repair March 2021...
Read More
Financial Results Half Year Ended 31 December 2020
Operations Update I Webinar CLINUVEL PHARMACEUTICALS LTD CLINUVEL PHARMACEUTICALS LTD will host...
Read More